Saturday 17 October 2026 Export RGC’s income statement to Excel — free account

Regencell Bioscience Holdings Limited

RGC Healthcare Drug Manufacturers Specialty & Generic

Dividend growth for three consecutive years.

9.59 0.07 +0.74%

Follow RGC

Alert me

Market cap: $4.7B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 4,720.00

Revenue —

Net Income (14.01)

Free Cash Flow (14.67)

Net Debt (2.36)

Current Ratio 1.42

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/FCF against its own 10 years 33.41%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	0.01	0.01
2017	0.02	0.01 0.01 0.01 0.01
2016	0.02	0.01 0.01 0.01 0.01

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	12	8	5	14
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	12	8	5	14

	2023	2024	2025	2026
Payables	—	—	—	—
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	0	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	3.65%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(8)
’25	—	—	—	—	(3)
’24	—	—	—	—	(4)
’23	—	—	—	—	(5)
’22	—	—	—	—	(5)
’21	—	—	—	—	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	(3)	(8)
’25	—	(3)	—	—	(3)
’24	—	(4)	—	—	(4)
’23	—	(5)	—	—	(5)
’22	—	(6)	—	—	(6)
’21	—	(1)	—	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(0.02)
’25	—	—	—	—	(0.01)
’24	—	—	—	—	(0.01)
’23	—	—	—	—	(0.01)
’22	—	—	—	—	(0.02)
’21	—	—	—	—	0.00

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	—	—	0.16	0.54	0.24	0.08	0.09	4.51	Analyst estimates 2027–2029 Powerpack
	High	—	—	—	—	1.55	1.27	0.87	0.85	83.60	69.00
People
People	Employees	—	—	—	8	13	13	12	12	10	—
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	—
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	0	(1)	(1)	(8)	(6)	(4)	(4)	(12)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	0	—	0	(1)	(1)	(8)	(6)	(4)	(4)	(12)
	Depreciation	—	—	—	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	0.00	0.00	0.00	(0.02)	(0.01)	(0.01)	(0.01)	(0.02)
	Cash flow	—	—	0.00	0.00	0.00	(0.01)	(0.01)	(0.01)	(0.01)	(0.02)
	Capex	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	0.00	0.00	0.00	(0.01)	(0.01)	(0.01)	(0.01)	(0.02)
	Book value	—	—	0.00	(0.01)	(0.01)	0.04	0.02	0.02	0.01	0.03
	Shares, m	—	—	380	380	380	487	494	494	494	495
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	0	(1)	(1)	(5)	(5)	(4)	(3)	(8)
	Capex	—	—	—	0	—	(1)	0	0	0	—
	Free cash flow	—	—	0	(1)	(1)	(6)	(5)	(4)	(3)	(8)
Balance, $m
Balance, $m	Working capital	—	—	(2)	(3)	(4)	16	11	8	4	13
	Total debt	—	—	2	3	—	1	0	—	—	—
	Net debt	—	—	0	0	0	(16)	(12)	(8)	(5)	(14)
	Shareholders’ equity	—	—	(2)	(3)	(4)	17	12	8	5	13
Returns, %
Returns, %	ROA	—	—	(321.41)	(214.55)	(315.35)	(81.11)	(38.32)	(40.85)	(50.50)	(114.25)
	ROIC	—	—	0.00	0.00	0.00	(717.14)	(923.47)	(1,149.68)	0.00	0.00
	ROE	—	—	17.42	36.19	40.51	(113.82)	(40.39)	(42.58)	(54.81)	(128.52)

Negative figures in brackets.

All 10 years →

Fundamentals updated 9 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%	Compare
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%	Compare
AMLX Amylyx Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	−100.61% (below 0%: shrinking)	n/m	−24.50% (below 0%: shrinking)	100.00%	0.00%	Compare
LQDA Liquidia Corporation	$3.1B	21.9×	18.5×	+1,842.73% (above 0%: growing)	n/m	+270.23% (above 0%: growing)	93.27%	49.81%	Compare
Median of peers	$6.2B	31.0×	25.3×	+20.27%	+37.50%	+9.32%	82.82%	13.73%

All 86 Drug Manufacturers Specialty & Generic stocks →